Article Text

Download PDFPDF
A simple risk index accurately predicted mortality in patients with ST elevation myocardial infarction

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

QUESTION: Can a simple risk index based on 3 routinely collected variables accurately predict mortality in patients with ST elevation myocardial infarction (MI)?

Design

Patient data from 3 multicentre randomised controlled trials were used for the development and validation of a risk index (Intravenous nPA for the Treatment of Infarcting Myocardium Early [InTIME II] Trial; and Thrombolysis and Thrombin Inhibition in Myocardial Infarction [TIMI] 9A and B trials).

Setting

>800 hospitals worldwide from the InTIME II trial for index development and {150 centres in the US, UK, Canada, Israel, and Germany}* from the TIMI 9A and B trials for index validation.

Patients

The development set comprised data from 13 253 patients who had ST elevation MI and were enrolled within 6 hours of symptom onset, and who did not have a history of cerebrovascular disease, systolic blood pressure (SBP) …

View Full Text

Footnotes

  • Source of funding: Bristol Myers Squibb sponsored the InTIME II trial.

  • For correspondence: Dr D A Morrow, Brigham and Women's Hospital, Boston, MA, USA. damorrow{at}bics.bwh.harvard.edu